Navigation Links
An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
Date:1/21/2009

Stelara Will Earn Decision Resources' Clinical Gold-Standard for Psoriasis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral agent for the treatment of moderate to severe psoriasis that demonstrates improved efficacy and lasting remission when compared with Amgen/Wyeth/Takeda's Enbrel would earn a higher patient share in the United States (20 percent) than in Europe (10 percent), according to surveyed U.S. and European dermatologists. Although the parenteral route of administration has not handicapped the performance of biological agents in the psoriasis market, oral therapies are still preferred by dermatologists for their convenience and the assumption that they will be priced lower than biological agents.

The new report entitled Psoriasis: Physicians Identify Key Differentiating Product Features in Crowded Market for Moderate to Severe Psoriasis finds that surveyed dermatologists indicate that a therapy's effect on psoriatic plaques at 10 or 12 weeks is the attribute that most influences their prescribing decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that emerging therapies, Centocor/Janssen-Cilag's Stelara, Abbott's ABT-874 and UCB/Otsuka's Cimzia, have advantages in this attribute over Enbrel, the psoriasis market sales leader. Following its likely approval in 2009 for moderate to severe psoriasis, Stelara will earn Decision Resources' proprietary clinical gold-standard for psoriasis from 2012 to 2017.

"Stelara's unique and most significant advantage among therapies for moderate to severe psoriasis is its effect on lasting remission," said Decision Resources Analyst Joanna Kim. "Interviewed experts believe that Stelara's notable efficacy, combined with its 12-week dosing interval, will position this agent to compete directly with agents in the TNF-alpha inhibitors drug class and will capture significant use as a first-line biologic in the psoriasis market."

About the Report

Psoriasis: Physicians Identify Key Differentiating Product Features in Crowded Market for Moderate to Severe Psoriasis is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. MassMutual Agent Honored by Insurance Industry for Extraordinary Service to Client
5. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
6. ABR-Affinity BioReagents Expands 100% Quality Guarantee
7. Inside job: new radioactive agents for colon cancer work inside cells
8. ABR -- Affinity BioReagents Announces Launch of New Website
9. The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing
10. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
11. Imagentix Offers Extension of Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 2016 , ... Hight-Doland Insurance Agency’s new community involvement program which serves families ... Sisters of Southwest Louisiana to help provide positive mentoring for local youth. Donations to ... Sisters of Southwest Louisiana has been helping to guide the area’s youth for over ...
(Date:5/4/2016)... Island (PRWEB) , ... May 04, 2016 , ... ... in April 2016. SS&A teamed up with one of the top website design ... information portal contains informative legal articles related to the law firm's main practice ...
(Date:5/4/2016)... ... May 04, 2016 , ... Recognizing that lifestyle medicine is essential to ... have tapped David Katz, MD, MPH, president of the American College of Lifestyle ... lifestyle medicine is especially gratifying,” said Katz. “There is so much opportunity to add ...
(Date:5/4/2016)... ... 04, 2016 , ... The preeminent surgical aftercare facility Pearl Recovery Retreat was ... surgery. In March 2016, the 61-year-old model and reality TV star was diagnosed with ... the milk ducts, according to an interview with the Daily Mail Online . ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... support for knees, ankles, and elbows. Engineered with athletes in mind, OMNIFORCE ... manufacturing (opposed to ineffective circular knitting, common in the industry) produces premium ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... Jerusalem announced today that it had signed an ... Inc. , developer of novel protein degradation and immunomodulatory ... and commercialization of drug candidates representing first-in-class therapy for ... were not disclosed. The novel technology was ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Ischemic Stroke ...  report to their offering.       ... Global Acute Ischemic Stroke Market and ... into Acute Ischemic Stroke pipeline products, Acute ...
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
Breaking Medicine Technology: